This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Nutritional and Metabolic Disorders  • Lipids and Lipid Disorders  • Statistics and Research Methods  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Mike Mitka

JAMA. 2008;299(19):2266.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Chicago—Controversy over the use of ezetimibe/simvastatin to prevent progression of atherosclerosis continues to grow.

At the American Academy of Cardiology's 57th Annual Scientific Session here in March, attendees packed the lecture hall to hear a detailed account of the ENHANCE (Effect of Ezetimibe Plus Simvastatin vs Simvastatin Alone on Atherosclerosis in the Carotid Artery) trial, 2 months after the company released the study's major findings to the media rather than to the scientific community. After the presentation, a panel assembled by the academy to put the findings in perspective declared that the aggressively marketed drug combination should be used only as a last resort in treating patients to decrease their levels of low-density lipoprotein cholesterol (LDL-C).

There is currently no evidence that ezetimibe, which reduces levels of low-density lipoprotein cholesterol (above), improves clinical outcomes such as myocardial infarction or death.

The ENHANCE trial's findings were presented on . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?